PURCHASE, NY, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Teladoc Health, the global leader in whole-person virtual care, today published its third annual corporate social responsibility (CSR) report. The report details the organization’s growing positive impact on communities, colleagues and clients around the globe.
“Our CSR work is fueled by our mission to empower all people everywhere to live their healthiest lives,” said Jason Gorevic, chief executive officer of Teladoc Health. “Together, we are building stronger, healthier communities and using our voice and our resources to expand equitable access to quality whole-person care.”
Key highlights from this year’s report include:
The report reflects a landmark year for Teladoc Health, which celebrated its 50 millionth visit and 20th anniversary in 2022.
“As a mission-driven organization, our values show up everything we do – from the products and experiences we build, to the quality of care we enable around the globe,” said Stephany Verstraete, chief marketing and engagement officer of Teladoc Health. “As we reflect on our twentieth year expanding access to care, we remain committed to building on our progress and increasing our impact in 2023.”
To view Teladoc Health’s full report and learn more about the company’s CSR efforts, click here.
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.
About Teladoc Health
Teladoc Health empowers all people everywhere to live their healthiest lives by transforming the healthcare experience. As the world leader in whole-person virtual care, Teladoc Health uses proprietary health signals and personalized interactions to drive better health outcomes across the full continuum of care, at every stage in a person’s health journey. Teladoc Health leverages more than two decades of expertise and data-driven insights to meet the growing virtual care needs of consumers and healthcare professionals. For more information, please visit www.teladochealth.com or follow @TeladocHealth on Twitter.
Last Trade: | US$9.99 |
Daily Change: | 0.06 0.60 |
Daily Volume: | 4,122,613 |
Market Cap: | US$1.720B |
November 25, 2024 October 30, 2024 July 31, 2024 July 16, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load